

Pharmacytes: An Ideal Vehicle for Targeted Drug Delivery

Robert A. Freitas, Jr.

Institute for Molecular Manufacturing, 555 Bryant Street, Suite 354, Palo Alto, California 94301, USA

An ideal nanotechnology-based drug delivery system is a pharmacyte—a self-powered, computer-controlled medical nanorobot system capable of digitally precise transport, timing, and targeted delivery of pharmaceutical agents to specific cellular and intracellular destinations within the human body. Pharmacytes may be constructed using future molecular manufacturing technologies such as diamond mechanosynthesis which are currently being investigated theoretically using quantum *ab initio* and density-functional computational methods. Pharmacytes will have many applications in nanomedicine such as initiation of apoptosis in cancer cells and direct control of cell signaling processes.

Keywords: Apoptosis, Cell Signaling, Drug Delivery, Microbivore, Microrobot, Nanomedicine, Nanomotor, Nanorobot, Nanotechnology, Pharmacyte, Respirocyte.

1. INTRODUCTION

What would an ideal drug delivery vehicle look like? To start with, it would be targetable not just to specific tissues or organs, but to individual cellular addresses within a tissue or organ. Alternatively, it would be targetable to all individual cells within a given tissue or organ that possessed a particular characteristic (e.g., all cancer cells, or all bacterial cells of a definite species, etc.). This ideal vehicle would be biocompatible and virtually 100% reliable, with all drug molecules being delivered only to the desired target cells and none being delivered elsewhere so that unwanted side effects are eliminated. The ideal vehicle would remain under the continuous control of the supervising physician, including post-administration. Even after the vehicles had been injected into the body, the doctor would still be able to activate or inactivate them remotely, or alter their mode of action or operational parameters. Once treatment was completed, all of the vehicles could be removed intact from the body, leaving no trace of their presence. Let's call this hypothetical ideal drug delivery vehicle a "pharmacyte."¹

The application of advanced nanotechnology to medicine, or nanomedicine¹⁻³—in particular, the future engineering discipline of medical nanorobotics—will eventually make possible the design, fabrication, and therapeutic deployment of pharmacytes. Pharmacytes will be self-powered, computer-controlled nanorobotic systems

capable of digitally precise transport, timing, and targeted delivery of pharmaceutical agents to specific cellular and intracellular destinations within the human body. Drug molecules could be purposely delivered to one cell, but not to an adjacent cell, in the same tissue. To fully appreciate the scope of this future development it is helpful to briefly review some of the background and recent history of medical nanorobotics.

2. FROM NANOPARTICLES TO NANOROBOTS

To bridge the gap in our knowledge between present-day nanoparticle-based technologies and future nanorobotic technologies, a great deal of research remains to be done. In the relatively near term, over the next 5 years, pre-nanorobotic nanomedicine can address many important medical problems by using nanoscale-structured materials and basic nanodevices for drug delivery that can already be manufactured today—most notably organic polymer or lipid-based systems such as polymeric micelles, liposomes and solid lipid nanoparticles, and various nanocrystal-based systems, many of which have already advanced to marketed products. Surveys of these technologies are available elsewhere,^{2,3} so here we consider just a few selected examples of nanoparticle-related work that may exemplify early steps toward the more sophisticated capabilities that nanorobots will ultimately possess.

Kopelman's group at the University of Michigan has developed dye-tagged nanoparticles to be inserted into

* Author to whom correspondence should be addressed.

nanorobots such as respirocytes and microbivores has been extensively reviewed in a book-length treatment elsewhere.³¹ Note that such devices will likely require some form of biocompatible coating^{31f} (depending on mission type and duration) to give them a high level of biocompatibility closer to that of lipid-based systems³² than to that of uncoated fullerene- or carbon nanotube-based systems.³³

3. PHARMACYTES

The exemplar pharmacyte would not be a relatively passive nanoparticle but rather would be a medical nanorobot 1–2 μm in size. It would be capable of carrying up to $\sim 1 \mu\text{m}^3$ of pharmaceutical payload stored in onboard tanks that are mechanically offloaded using molecular sorting pumps^{1a,21} mounted in the hull, operated under the control of an onboard computer. Depending on mission requirements, the payload can be discharged into the proximate extracellular fluid^{1s} or delivered directly into the cytosol using a transmembrane injector mechanism.^{1p–1r,31k} The sorting pumps are typically envisioned as $\sim 1000 \text{ nm}^3$ -size devices that can transfer $\sim 10^6$ molecules/sec.^{1a} Each pump employs reversible binding sites mounted on a rotating structure that cycles between the interior and exterior of the nanorobot, allowing transport of a specific molecule even against a considerable concentration gradient. Other reversible binding sites comprise sensors on the surface of the nanorobot in order to recognize the unique biochemical signature of specific vascular and cellular addresses,^{1b} simultaneously testing encountered biological surfaces for a sufficiently reliable combination (at least 5–10 in number) of positive-pass and negative-pass molecular markers to ensure virtually 100% targeting accuracy. Onboard power may be provided by glucose and oxygen drawn from the local environment (e.g., circulating blood, interstitial fluid, or cytosol) that is metabolized using fuel cells^{1c} or other methods^{1d} of biochemical energy conversion. If needed for a particular application, deployable mechanical cilia^{1e} and other locomotive systems^{1f} can be added to the pharmacyte to permit transvascular^{1g} and transcellular^{1h} mobility, thus allowing delivery of pharmaceutical molecules to specific cellular and even intracellular addresses with negligible error. Because sorting pumps can be operated reversibly, pharmacytes could also be used to selectively extract specific molecules from targeted locations as well as deposit them. Pharmacytes, once depleted of their payloads or having completed their mission, would be recovered from the patient via centrifuge nanopheresis¹ⁱ or by conventional excretory pathways. The nanorobots might then be recharged, reprogrammed and recycled for use in a second patient who may need a different pharmaceutical agent targeted to different tissues or cells than in the first patient.

Phagocytosis^{31d} and foreign-body granulomatous reaction^{31e} are major issues for all medical nanorobots

intended to remain in the body for extended durations, though short-duration pharmacytes that can quickly be extracted from the body¹ⁱ may face somewhat fewer difficulties. In either case, bloodborne 1–2 μm pharmacytes can avoid clearance by the RES (whether via geometrical trapping^{31g} or phagocytic uptake^{31h}) and techniques have been proposed for phagocyte avoidance and escape³¹ⁱ at each step in the phagocytic process. Pharmacytes will not embolize small blood vessels because the minimum viable human capillary that allows passage of intact erythrocytes and white cells is 3–4 μm in diameter, which is larger than the largest proposed pharmacyte. Pharmacytes can also be equipped with mobility systems^{1e,1f} to allow mechanically-assisted passage through partially occluded vessels or unusually narrow spaces such as the interendothelial slits of the spleen.^{31j} Targeting ligands or receptors in the cell membrane exterior can be recognized by chemotactic sensors^{1t} on the nanorobot surface, but note that the pharmacyte (as distinguished from conventional nanoparticles) need not always be endocytosed. For example, in some cases nanorobots may use transmembrane mechanical nanoinjectors^{31k} to avoid having to enter a target cell. Alternatively, if the mission requires cytopenetration then endocytosis of the nanorobot may be stimulated using biomimetic^{1u} or completely artificial^{1h} (including powered mechanical) methods; after payload delivery, indigestible diamondoid nanorobots will require exocytosis by similar means. Nanorobot volume is only 1–10 μm^3 compared to 10^3 – $10^4 \mu\text{m}^3$ for most human tissue cells so pharmacytes could be targeted to an intracellular organelle, though nanorobots would have insufficient room to enter one (excepting perhaps the ER and nucleus) and would have to rely on nano-injection in those cases.

There are many potential uses of pharmacytes but it will suffice to briefly mention just two general classes of applications.

First, it is often desired to deliver cytotoxic agents to tumor cells. Current methods involve introducing large quantities of chemotherapy agents into the body in an effort to kill a relatively few cancerous cells, with numerous unwanted side effects on healthy cells. Precise targeting using pharmacytes can ensure delivery only to the correct cellular addresses, with presentation of cytotoxic chemical agents literally on a cell-by-cell basis. In one trivial scenario, the targeted killing of 1 billion (10^9) cancer cells with each cell capable of being killed by $\sim 10^6$ precisely-delivered ~ 1000 -dalton cytotoxic molecules (i.e., lethality similar to bufagin toxin) would require a total whole-body treatment dose of just $\sim 10^{15}$ cytotoxic molecules or $\sim 0.001 \text{ mm}^3$ ($\sim 2 \mu\text{g}$) of delivered material. This dose could be carried and dispensed by one trillion pharmacyte nanorobots (total injected volume of therapeutic nanorobots $\sim 2 \text{ cm}^3$) assuming that only 0.1% of the nanorobots encounter an acceptable target and are

allowed to release a $0.001 \mu\text{m}^3$ cytotoxic payload into the targeted cell, while the remaining 99.9% of the nanorobots release nothing. After initiating cell death, unmetabolized free cytotoxic molecules can be locally reacquired by the pharmacy and subsequently transported out of the patient, thus minimizing any post-treatment collateral damage. Note that the strict size requirements for macromolecules to reach the leaky vasculature of a tumor and convectively enter its pores³⁴ may apply to passively-diffusing payload molecules which might be conveyed and released by pharmacies, but these limits do not apply to the motorized active nanorobots themselves. Upon arriving in the vicinity of a tumor, the pharmacy may deliver its payload either via direct nano-injection^{31k} (for tumor cells adjoining the vasculature) or by progressive cytopenetration^{lh} through adjacent cells until the targeted tumor cell that awaits payload delivery is reached.

It is well-known that apoptotic cellular “death receptors” can be expressed on both normal and cancerous cells in the human body, so one challenge for conventional drug-based therapy is to find some way to activate death receptors selectively on cancer cells only.³⁵ With pharmacies, such selectivity should be simple and routine using multiple chemosensors,^{lj} a benefit that may be characteristic of most future nanorobot-based therapeutics. For example, if caspase cascade amplification is sufficient to permit single-site activation of the cascade, then in principle an extracellular nanorobot intending cytotoxicity of a detected cancerous cell could press onto the outer surface of the target cell an appropriate ligand display tool. This tool might contain suitably exposed trimeric CD95L (aka. FasL) ligand (binds to the extracellular domains of three CD95 death receptors), TNF or lymphotoxin alpha (binds to CD120a), Apo3L ligand aka TWEAK (binds to DR3), or Apo2L ligand aka TRAIL (binds to DR4 and DR5).^{35,36} The binding event would then activate a single death receptor complex, potentially triggering the entire irreversible cytotoxic cascade. If necessary, multiple such display tools could be employed. This technique avoids much of the storage requirement for bulky consumables aboard the medical nanorobot. As another approach, molecular sorting pumps on the pharmacy surface could be used to selectively extract from the cytoplasm of a target cell specific crucial molecular species of IAPs (Inhibitors of Apoptosis) that normally hold the apoptotic process in check. Examples include survivin, commonly found in human cancer cells,³⁷ the transcription factor NF- κ B, and Akt, which delivers a survival signal that inhibits the apoptosis induced by growth factor withdrawal in neurons, fibroblasts, and lymphoid cells. Conversely, decoy receptors (DcRs)³⁸ that compete with DR4 and DR5 for binding to Apo2L could be saturated with intrinsically harmless but precisely engineered intracellular “chaff” ligands. With IAPs removed or DcRs blocked, apoptosis may be free to proceed.

Pharmacies could also tag target cells with biochemical substances capable of triggering a reaction by the body's

natural defensive or scavenging systems, a strategy called “phagocytic flagging”.^{lk} For example, novel recognition molecules are expressed on the surface of apoptotic cells. In the case of T lymphocytes, one such molecule is phosphatidylserine, a lipid that is normally restricted to the inner side of the plasma membrane^{lm} but, after the induction of apoptosis, appears on the outside.³⁹ Cells bearing this molecule on their surface can then be recognized and removed by phagocytic cells. Seeding the outer wall of a target cell with phosphatidylserine or other molecules with similar action could activate phagocytic behavior by macrophages, which had mistakenly identified the target cell as apoptotic. Loading the target cell membrane surface with B7 costimulator molecules also permits T-cell recognition, allowing an immunologic response via the immunological synapse.⁴⁰ These tagging operations should work well against cells that have an apoptotic response that can be triggered by cytotoxic T cells—such as human cancer cells and cysts.

A second major application area of pharmacies would be the control of cell signaling processes. As a trivial example, Ca^{++} serves as an intracellular mediator in a wide variety of cell responses including secretion, cell proliferation, neurotransmission, cellular metabolism (when complexed to calmodulin), and signal cascade events that are regulated by calcium-calmodulin-dependent protein kinases and adenylate cyclases. The concentration of free Ca^{++} in the extracellular fluid or in the cell's internal calcium sequestering compartment (which is loaded with a binding protein called calsequestrin) is $\sim 10^{-3}$ ions/ nm^3 . However, in the cytosol, free Ca^{++} concentration varies from 6×10^{-8} ions/ nm^3 for a resting cell up to 3×10^{-6} ions/ nm^3 when the cell is activated by an extracellular signal; cytosolic levels $> 10^{-5}$ ions/ nm^3 may be toxic, e.g., via apoptosis. To transmit an artificial Ca^{++} activation signal to a typical $(20 \mu\text{m})^3$ tissue cell in ~ 1 msec, a single pharmacy stationed in the cytoplasm must promptly raise the cytosolic ion count from 480,000 Ca^{++} ions to 24 million Ca^{++} ions. This is a transfer rate of $\sim 2.4 \times 10^{10}$ ions/sec which may be accomplished using $\sim 24,000$ hull-mounted molecular sorting pumps^{la} across a total nanorobot emission surface area of $\sim 2.4 \mu\text{m}^2$. Onboard storage volume of $\sim 1 \mu\text{m}^3$ can hold up to ~ 20 billion calcium atoms, enough to transmit up to ~ 1000 artificial Ca^{++} signals into the cell even assuming no reabsorption and recycling of the ions.

Properly configured *in cyto* pharmacies could also modify natural intracellular message traffic according to preprogrammed rules or by following external commands issued by the supervising physician. In the case of steroids and thyroid hormones, this may involve the direct manipulation of the signaling molecules themselves (after they have passed through the cell membrane) or their bound receptor complexes. However, most signaling molecules are absorbed at the cell surface, initiating a

signal cascade which may be modulated by manipulating second-messenger molecules or other components of the *in cyto* signal cascade. A few basic examples of signal modifying action involving cAMP would include:

(A) *Amplification*. A single epinephrine molecule received by a beta adrenergic receptor at a cell surface transduces the activation of dozens of G-protein alpha subunits, each of which in turn activates a single adenylate cyclase enzyme which cyclizes hundreds of ATP molecules into cAMP molecules. The intracellular population of cAMP (in muscle or liver target cells) is normally $<10^{-6}$ M or ~ 5 million molecules for a typical $(20 \mu\text{m})^3$ tissue cell. Stimulation by epinephrine raises the cAMP population to ~ 25 million molecules in a few seconds. However, upon detecting this rising tide of cAMP during the first few msec, each *in cyto* pharmacy could quickly amplify this existing chemical signal by releasing 20 million cAMP molecules (occupying a storage volume of $\sim 0.01 \mu\text{m}^3$) from onboard inventories in ~ 1 msec—thus accelerating cellular response time by several orders of magnitude.

(B) *Suppression*. Similarly, upon detection of rising cAMP levels in target cells, resident pharmacies could use molecular pumps to rapidly remove cAMP from the cytosol as quickly as it is formed, even under maximum adrenal stimulation. The diffusion-limited intake current at the basal concentration ($\sim 6 \times 10^{-7}$ molecules/ nm^3) for a cAMP-absorbing spherical nanodevice $1 \mu\text{m}$ in radius is ~ 4 million molecules/sec,¹ⁿ so a single such device could probably keep up with natural cAMP production rates and thus completely extinguish the response by preserving a flat basal concentration even in the face of a maximum stimulus. (As a practical matter, it may be more efficient to control epinephrine generation at its glandular source unless it is desired to interface with just a single tissue type.) Simultaneously, the cAMP-absorbing nanorobot may hydrolyze the stored cAMP in the manner of the cAMP phosphodiesterases, then excrete these deactivated AMP messenger molecules back into the cytosol. Similar methods might be useful in ligand-gated ion channel desensitization or in disease symptom suppression—as, for example, in suppressing the prolonged elevation of cAMP in intestinal epithelial cells associated with the cholera toxin, that produces severe diarrhea by causing a large influx of water into the gut.

(C) *Replacement*. Combining suppression and amplification, an existing chemical signal could be eliminated and replaced by a different—even an opposite—message pathway using pharmacy mediators. Alternative pathways may be natural or wholly synthetic. Novel responses to existing signals may be established within the cell to enhance functionality or to improve stability or controllability. For instance, detection of one species of cytokine by a pharmacy could trigger rapid specific absorption of that cytokine and a simultaneous fast release of another (different) species of cytokine in its place. Such procedures

must of course take into account the many redundant signaling pathways and backup systems (e.g., developmental signals, immune system, blood clotting) that exist within the cell. Medical nanorobots can allow the replacement of many redundant pathways with more refined and specific responses.

(D) *Linkage*. Previously unlinked signal cascades may be artificially linked using *in cyto* nanorobots. As a fanciful example, the receipt of epinephrine by pharmacies located in the capillaries of the brain could trigger these devices to suppress the adrenalin response while simultaneously releasing chemical messengers producing message cascades that stimulate production of enkephalins or other opioids, thus encouraging a subjective state of psychological relaxation rather than the “fight or flight” response to certain stressful conditions.

References and Notes

1. R. A. Freitas, Jr., *Nanomedicine, Volume I: Basic Capabilities*, Landes Bioscience, Georgetown, TX (1999); Sections (a) 3.4.2, (b) 8.5.2.2, (c) 6.3.4.5, (d) 6.3.4, (e) 9.3.1, (f) 9.4, (g) 9.4.4.1, (h) 9.4.5, (i) 10.3.6, (j) 4.2, (k) 10.4.1.2, (m) 8.5.3.2, (n) 3.2.2, (o) 8.2.1.2, (p) 9.2.4, (q) 9.2.5, (r) 10.4.2.1, (s) 9.2.6, (t) 4.2.8, (u) 9.4.5.4; <http://www.nanomedicine.com/NMI.htm>.
2. R. A. Freitas, Jr., *Nanomedicine: Nanotech. Biol. Med.* 1, 2 (2005).
3. R. A. Freitas, Jr., *J. Comput. Theor. Nanosci.* 2, 1 (2005).
4. W. Tang, H. Xu, R. Kopelman, and M. A. Philbert, *Photochem. Photobiol.* 81, 242 (2005).
5. X. Shi, I. J. Majoros, and J. R. Baker, Jr., *Mol. Pharm.* 2, 278 (2005).
6. “Tecto-Dendrimers,” Michigan Nanotechnology Institute for Medicine and Biological Sciences (2005); <http://nano.med/edu.projects/tecto-dendrimers.htm>.
7. K. Ishiyama, M. Sendoh, and K. I. Arai, *J. Magnetism Magnetic Mater.* 242–245, 1163 (2002).
8. J. B. Mathieu, S. Martel, L. Yahia, G. Soulez, and G. Beaudoin, *Biomed. Mater. Eng.* 15, 367 (2005).
9. K. B. Yesin, P. Exner, K. Vollmers, and B. J. Nelson, in *8th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI)*, p. 819 (2005).
10. D. D. Chrusch, B. W. Podaima, and R. Gordon, in Conf. Proc. 2002 IEEE Canadian Conference on Electrical and Computer Engineering, edited by W. Kinsner and A. Sebak, IEEE (2002).
11. K. Hamad-Schifferli, J. J. Schwartz, A. T. Santos, S. Zhang, and J. M. Jacobson, *Nature* 415, 152 (2002).
12. R. F. Service, *Science* 298, 2322 (2002).
13. T. R. Kelly, H. De Silva, and R. A. Silva, *Nature* 401, 150 (1999).
14. T. J. Huang, W. Lu, H.-R. Tseng, B. Brough, A. Flood, B.-D. Yu, J. F. Stoddart, and C.-M. Ho, *11th Foresight Conf. Mol. Nanotech.* (2003).
15. D. A. Leigh, J. K. Y. Wong, F. Dehez, and F. Zerbetto, *Nature* 424, 174 (2003).
16. N. Koumura, R. W. Zijlstra, R. A. van Delden, N. Harada, and B. L. Feringa, *Nature* 401, 152 (1999).
17. J. Cumings and A. Zettl, *Science* 289, 602 (2000).
18. A. M. Fennimore, T. D. Yuzvinsky, W.-Q. Han, M. S. Fuhrer, J. Cumings and A. Zettl, *Nature* 424, 408 (2003).
19. Y. Shirai, A. J. Osgood, Y. Zhao, K. F. Kelly, and J. M. Tour, *Nano Lett.* 5 (2005).
20. “Rice Scientists Build World’s First Single-molecule Car” (2005) <http://www.sciencedaily.com/releases/2005/10/051021021040.htm>.
21. K. E. Drexler, “Nanosystems: Molecular Machinery, Manufacturing, and Computation,” John Wiley & Sons, New York (1992).

22. R. C. Merkle and R. A. Freitas, Jr., *J. Nanosci. Nanotechnol.* 3, 319 (2003).
23. N. Oyabu, O. Custance, I. Yi, Y. Sugawara, and S. Morita, *Phys. Rev. Lett.* 90, 176102 (2003).
24. R. A. Freitas, Jr., A Simple Tool for Positional Diamond Mechnosynthesis, and its Method of Manufacture, U.S. Provisional Patent Appl. No. 60/543,802, U. S. Patent Pending (2005).
25. R. A. Freitas, Jr. and R. C. Merkle, Kinematic Self-Replicating Machines, Landes Bioscience, Georgetown, TX (2004); <http://www.molecularassembler.com/KSRM.htm>.
26. P. Vettiger, G. Cross, M. Despont, U. Drechsler, U. Duerig, B. Gotsmann, W. Haerberle, M. Lantz, H. Rothuizen, R. Stutz, and G. Binnig, *IEEE Trans. Nanotechnol.* 1, 39 (2002).
27. D. Bullen, S. Chung, X. Wang, J. Zou, C. Liu, and C. Mirkin, *Proc. Mat. Res. Soc.* 758, LL4.2.1 (2002).
28. S. Martel and I. Hunter, *Proceedings of the 3rd International Workshop on Microfactories IWMF'02*, Carnegie Mellon Univ. Robotics Institute (2002), p. 97.
29. R. A. Freitas, Jr., *Artif. Cells Blood Subst. Immobil. Biotech.* 26, 411 (1998).
30. R. A. Freitas, Jr., *J. Evol. Technol.* 14, 1 (2005).
31. R. A. Freitas, Jr., *Nanomedicine, Volume IIA: Biocompatibility*, Landes Bioscience, Georgetown, TX (2003); Sections (a) 15.2, (b) 15.2.3, (c) 15.2.5, (d) 15.4.3, (e) 15.4.3.5, (f) 15.2.2, (g) 15.4.2, (h) 15.4.3.2, (i) 15.4.3.6, (j) 15.4.2.3, (k) 15.5.7.2.3; <http://www.nanomedicine.com/NMIIA.htm>.
32. J. M. Koziara, J. J. Oh, W. S. Akers, S. P. Ferraris, and R. J. Mumper, *Pharm. Res.* 22, 1821 (2005).
33. A. Radomski, P. Jurasz, D. Alonso-Escolano, M. Drews, M. Morandi, T. Malinski, and M. W. Radomski, *Br. J. Pharmacol.* 146, 882 (2005).
34. E. B. Brown, Y. Boucher, S. Nasser, and R. K. Jain, *Microvasc. Res.* 67, 231 (2004).
35. A. Ashkenazi and V. M. Dixit, *Science* 281, 1305 (1998).
36. G. Pan, K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni and V. M. Dixit, *Science* 276, 111 (1997).
37. G. Ambrosini, C. Adida, and D. C. Altieri, *Nature Med.* 3, 917 (1997).
38. J. P. Sheridan, S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, and A. Ashkenazi, *Science* 277, 818 (1997).
39. V. A. Fadok, D. R. Voelker, P. A. Campbell, J. J. Cohen, D. L. Bratton, and P. M. Henson, *J. Immunol.* 148, 2207 (1992).
40. A. Grakoui, S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin, *Science* 285, 221 (1999).

Received: 2 November 2005. Revised/Accepted: 29 November 2005.